USAN Watch - April 2012
USAN | Research Code | Structure | Drug Class | Therapeutic class | Target |
alirocumab | REGN-727, SAR-0236553 | mAb | therapeutic | PCSK9 | |
birinapant | TL-32711 | synthetic small molecule | therapeutic | IAPs | |
bevenopran | CB-5945 | synthetic small molecule | therapeutic | mu opioid receptor | |
camicinal | GSK-962040B |
| synthetic small molecule | therapeutic | motilin receptor |
cindunistat | PHA-84250, SC-084250, PF-00572986 | synthetic small molecule | therapeutic | NOS? | |
danirixin | GSK-1325756B | synthetic small molecule | therapeutic | CXCR2 | |
demcizumab | OMP-21M18 | mAb | therapeutic | DLL4 | |
elubrixin, elubrixin tosylate | SB-656933-AAF, SB-656933-AAA | synthetic small molecule | therapeutic | CXCR2 | |
etirinotecan pegol, etirinotecan pegol tetrahydrochloride, etirinotecan pegol tetratriflutate | NKTR-102 | natural product-derived small molecule | therapeutic | topoisomerase 1 | |
fasinumab | REGN-475, SAR-164877 | mAb | therapeutic | NGF | |
lomibuvir | VX-222 | synthetic small molecule | therapeutic | HCV NS5B polymerase | |
mafodotin | mc-MMAF, mcMMAF, SGD-1269, monomethyl auristatin F |
| peptide | therapeutic | tubulin |
neceprevir | ACH-0142684 | synthetic small molecule | therapeutic | ||
pexastimogene devacirepvec | JX-594 | virus | therapeutic | ||
rabusertib | LY-2603618 | synthetic small molecule | therapeutic | CHEK1 CHEK2 | |
rilimogene galvacirepvec | Prostvac-V | virus | therapeutic | ||
sebelipase alfa | SBC-102 | enzyme | therapeutic | ||
vercirnon | GSK-1605786, CCX-282 | synthetic small molecule | therapeutic | CCR9 | |
vintafolide | EC-145 | natural product-derived small molecule | therapeutic | Folate Receptor, tubulin | |
vorsetuzumab | SGN-70 | mAb | therapeutic | CD70 | |
vorsetuzumab mafodotin | SGN-75 | mAb ADC | therapeutic | CD70 |
I knocked this together during a meeting ( :O ) so there may be some errors, feel free to add more detail/corrections in the comments.
A couple of extras have appeared on the USAN web page recently.... so I've updated the table above appropriately. Well, two more have appeared on the USAN site! Will add these soon. It looks like there are some subtle rejigging of the business rules for USANs - in particular the assignment of a USAN for the drug conjugate mafoditin - I do wish that the USAN office would reply to emailed questions.....
A couple of extras have appeared on the USAN web page recently.... so I've updated the table above appropriately. Well, two more have appeared on the USAN site! Will add these soon. It looks like there are some subtle rejigging of the business rules for USANs - in particular the assignment of a USAN for the drug conjugate mafoditin - I do wish that the USAN office would reply to emailed questions.....